AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A meta-analysis of seven placebo-controlled trials found that neurokinin-receptor antagonists were associated with improved patient-reported sleep disturbance among menopausal women with moderate-to-severe hot flashes. The reported benefit appeared by four weeks, but the analysis does not show whether sleep improved independently of hot-flash relief or which drug works better in a direct comparison.

A meta-analysis of seven placebo-controlled trials found that neurokinin-receptor antagonists used for menopausal hot flashes were associated with improved patient-reported sleep disturbance, with differences from placebo apparent as early as four weeks. The findings, presented at the Menopause Society annual meeting and reported by MedPage Today, offer additional evidence for women seeking nonhormonal treatment, though they do not establish that the drugs improve sleep separately from their effect on hot flashes.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The analysis covered 3,184 women with moderate-to-severe vasomotor symptoms: 949 received fezolinetant, 864 received elinzanetant, and 1,371 received placebo. Across the pooled results, the researchers reported sleep-disturbance improvements compared with placebo at four, 12 and 24 weeks. The reported standardized mean differences were -3.94 at four weeks, -3.11 at 12 weeks and -2.04 at 24 weeks; the confidence interval at 24 weeks was -3.93 to -0.15.

Five trials used the same validated PROMIS Sleep Disturbance Short Form questionnaire and were pooled for the primary outcome. It asks about sleep quality, restfulness and difficulty falling or staying asleep over the previous seven days; lower scores indicate less disturbance. The remaining two trials used different measures and were considered separately. The included trials were assessed as having a low risk of bias, according to the report.

In subgroup analyses, both drugs significantly improved sleep through 12 weeks. The analysis reported a larger effect for elinzanetant than fezolinetant at four weeks and 12 weeks, but the drugs were not compared in a head-to-head trial. The estimates are comparisons within trial data, not proof that one medicine is superior for an individual patient.

At a glance
reportWhen: Presented October 22, 2026; included tr…
The developmentA meta-analysis presented at the Menopause Society annual meeting found sleep-disturbance improvements in trial data for two nonhormonal drugs used to treat menopausal vasomotor symptoms.

Sleep Outcomes Beyond Hot Flashes

Sleep disruption can be a major complaint for people experiencing menopausal hot flashes. The results add evidence about an outcome that, according to the researchers, had generally been measured as a secondary endpoint in the larger drug trials rather than examined in a dedicated meta-analysis. That may help clinicians and patients discuss whether a treatment aimed at vasomotor symptoms could also support better sleep.

The findings are relevant to people who cannot use hormone therapy or prefer not to. They do not establish that these medicines are suitable for everyone, or that they should be prescribed specifically as sleep treatments. The analysis measured reported sleep disturbance among trial participants treated for vasomotor symptoms; it does not replace individual medical advice or establish a separate effect on sleep disorders.

Products Worth Considering

As an affiliate, we earn on qualifying purchases.

Two Nonhormonal Drugs in Review

Menopausal hormone therapy is described in the source report as the preferred treatment for vasomotor symptoms, but some women have contraindications or choose a nonhormonal option. Fezolinetant, marketed as Veozah, blocks the NK3 receptor; elinzanetant, marketed as Lynkuet, blocks NK1 and NK3 receptors. These medicines act on pathways involved in the brain’s regulation of body temperature, which can help reduce hot flashes.

Maria Julia Lemos, MD, of Kurah Women’s Health Institute in Brazil, and colleagues conducted the systematic review. They searched PubMed, Embase and Cochrane records from their inception through May 2026 and included seven placebo-controlled trials. The analysis brought together data from trials including OASIS, SWITCH-1, DAYLIGHT, SKYLIGHT and a 2019 study by Depypere.

“They may help women sleep better, not just have fewer hot flashes.”

— Maria Julia Lemos, MD, lead researcher, speaking to MedPage Today

Limits of the Sleep Findings

The researchers cited a small number of eligible trials, differences among participants, treatment regimens and follow-up periods, and reliance on patient-reported sleep outcomes. Because sleep disturbance and hot flashes can change together, the analysis could not determine how much of the sleep improvement was independent of broader vasomotor symptom relief.

The reported drug subgroup differences also do not settle which treatment is more effective: direct head-to-head trials are still needed, Lemos said. The source report does not provide enough information to infer that the observed effect will apply equally to every patient or to people without menopausal vasomotor symptoms.

Direct Comparisons Remain Needed

The next evidence milestone is a direct comparison of fezolinetant and elinzanetant, which could help clarify the apparent difference between their subgroup estimates. The researchers also identified the need for more evidence on sleep outcomes and on how those outcomes relate to changes in hot flashes. No further study timetable was given in the report.

For now, the findings add a sleep-related result to the evidence on these drugs as treatments for menopausal vasomotor symptoms. Treatment choices remain a matter for patients and clinicians to discuss, taking account of individual circumstances and the available evidence.

Key Questions

Which drugs were included in the analysis?

The analysis included fezolinetant and elinzanetant, nonhormonal neurokinin-receptor antagonists used for menopausal vasomotor symptoms.

How soon was a sleep benefit reported?

The pooled analysis reported a difference from placebo as early as four weeks, with improvements also reported at 12 and 24 weeks. These were patient-reported sleep-disturbance outcomes in trial participants.

Does the study show that these medicines treat insomnia?

No. The analysis examined sleep disturbance among women being treated for moderate-to-severe menopausal vasomotor symptoms. It does not establish the drugs as treatments for insomnia or show that sleep improved independently of hot-flash relief.

Does the analysis show that elinzanetant works better?

Subgroup estimates showed a larger effect for elinzanetant at four and 12 weeks, but the medicines were not tested against each other in a head-to-head trial. The researchers said direct comparisons are still needed.

Source: rss

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

CTE In NFL Players: What A New Study Tells Us — And What It Doesn’t

A model estimates CTE in 74.5% of former NFL players who died from 2008 to 2023, but the result does not describe living players or other athletes.

Bella Hadid tears up about ‘severe’ latest Lyme disease flare-up

Supermodel Bella Hadid revealed she experienced a severe Lyme disease flare-up, sharing emotional details about her health struggles publicly for the first time.

Theravance Biopharma Surges In Global Coverage

Theravance Biopharma experiences a significant increase in international media mentions, indicating rising global interest and potential strategic developments.

Christa Pike’s Survival Wasn’t A Miracle. That’s What Should Scare Us.

Christa Pike survived a Tennessee lethal-injection attempt and was taken off a ventilator. The state has ordered an independent review.